In case anyone is wondering how long it may take before a

New Post Public Reply Private Reply Replies (1) Message Board
joey68
In case anyone is wondering how long it may take before a run occurs..

It's important to be practical. First off, a run may never occur. As much as we want them to succeed, the company could fail just as easily as it could bring in revenue. Being invested doesn't equate to success.

Although I don't believe SCIE will fail, I try to think rationally with my investments. I don't have a need for 50 million shares in any one company, and I never fall for the 'buy more while you still can' fluff.

I'd rather have 1 million shares in 10 companies, therefor increasing my chance of success, than have 10 million shares in one company and watch that one fail.

The link below is a comparative study between SCIE and AVX$. Remember, comparing two companies does not mean in any way that they will react the same. The reason I chose to mention AVX$ was because it showed similar attributes to what SCIE is showing right now.

http://i.imgur.com/ot9mQOi.jpg

As you can see, the chart for AVX$ is displayed as it would look prior to the 1 for 4 reverse split which occurred Oct 7, 2015.

Notice how the PPS flatlined for well over a year. During this time, no investor knew what was going to happen. Many investors sold at a loss because nothing was happening for so long. Nay-sayers were 'winning' the online forum war by constantly bombarding investors with doom and gloom posts.

and yet, notice how, even prior to the RS, it went from .27 cents to $1.94 in less than 6 months. Following this, the PPS increased after the RS and skyrocketed to almost $15 in less than a month.

Notice the similarities in volume between AVX$ and SCIE. for years AVX$ had almost no volume and then volume started showing up out of nowhere; exactly like SCIE is doing right now.

Remember, I am not saying that what happened with AVX$ will happen to SCIE. Im simply saying that if SCIE does have a run, it could take some time before it actually happens. Im also saying that the chart is lining up for a run. Again, the big questions is, 'how long will the chart remain flatlined prior to this run?'

In the meantime, if I had to draw any conclusions, and I could be completely wrong, I believe the upcoming 10-K will show sales. I also know that SCIE has debt which needs to be taken care of, and hopefully these sales will assist in that. I think after the 10-K, we might see a PPS of around .002 but that's pure speculation.

What I do know is that if you look at the bolinger bands on a year chart, the bands were very far apart (high volatility), and now they are very close together (low volatility). Typically, high periods follow periods of low volatility which means that we should see some form of action this year. Of course, it all depends on the company and what the 10-K and the next 10-Qs say.

Think about..
1. Did we have sales?
2. We know SCIE has ongoing studies right now:
http://clinicaltrials.gov/ct2/show/NCT01980134

We know these studies were verified April 2014 by SpectraScience, which is almost 2 years ago, which means we should get results of some sort shortly.

In fact, and this just popped into my head, that last PR which mentioned results of the study by Dr. Helmut Neumann will be published in Endoscopy magazine. I wonder, is it possible the results are from these studies?? Maybe, maybe not; time will tell.

3. We know the study was published (last PR said so), so we have that to look forward to.
4. We know 5+ countries have the WavSTAT4 in their hospitals and are using it as we speak.

The 'knowns' in my opinion outweigh the 'unknowns'. We know a lot, we just have to wait for the PRs and SEC filings to tell us the other stuff.

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 4

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 5

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Caledon Farms Unveils New Gently Cooked Dog Food Line

Updated Category News Views 264

Caledon Farms Introduces Gently Cooked Dog Food In an exciting move, The Crump Group Inc. is launching a new line of gently cooked dog food under the Caledon Farms brand. This innovative product aims to deliver wholesome and nutritious meals for dogs, featuring high-quality ingredients that pet owners can trust. With its fresh frozen meals, Caledon Farms promises a...

Continue Reading
Air2O's Strategic Partnerships Set to Transform HVAC in 2026

Updated Category News Views 111

Revolutionizing HVAC: The Importance of Partnerships in 2026 As we move closer to a new era in the HVAC industry, industry leaders are beginning to recognize a significant shift in strategy. In the next few years, the focus will not solely lie on advanced technology, but rather on collaborative partnerships. This approach is a response to the growing complexity and...

Continue Reading
ZenaTech Expands Global Presence with New Drone Manufacturing Hub

Updated Category News Views 58

ZenaTech Expands Global Presence with New Drone Manufacturing Hub ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q), a company renowned for its advancements in artificial intelligence drone solutions and enterprise software-as-a-service applications, is making significant strides in its operational footprint. Currently, executives from ZenaTech are participating in a Trade Mission...

Continue Reading
Criteo's Quarterly Performance Drives Strong Results and Growth

Updated Category News Views 155

Overview of Criteo's First Quarter 2025 Financial Results Criteo S.A. (NASDAQ: CRTO), a leading commerce media company, reported robust financial performance for the first quarter of 2025, demonstrating its operational agility and strategic growth initiatives. This quarter, Criteo deployed $56 million towards repurchasing shares, emphasizing its commitment to enhancing...

Continue Reading
Snail Inc. Expands Footprint in Global Short Drama Market

Updated Category News Views 250

Snail Inc. Drives Growth in Short Drama with Recent Recognition Snail, Inc. (Nasdaq: SNAL), a premier developer and publisher within the realm of interactive digital entertainment, has taken a significant step in expanding its global presence through the recent nomination of its Short Drama, Hollywood Heartthrob, for the International Short Drama Awards. This nomination...

Continue Reading